Hit Finding
Hit to Lead
Lead
Optimisation
Pre-clinical
Development/CMC
  • ELN 28 first-in-class 87% 87%
  • ELN 201 79% 79%
  • ELN 27 30% 30%
  • ELN 71 first-in-class 73% 73%
  • ELN 719 first-in-class 65% 65%
  • ROR1 Drug Conjugate 95% 95%
  • Bi-specific Drug Conjugate 90% 90%

Hit Finding

Hit to Lead

Lead

Optimisation

Pre-clinical

Development

CMC

PARTNER

  • ELN28 first-in-class 87% 87%
  • ELN 201 79% 79%
  • ELN 27 30% 30%
  • ELN 71 first-in-class 73% 73%
  • ELN 719 first in class 65% 65%
  • ROR1 Drug Conjugate 95% 95%
  • Bi-specific Drug Conjugate 90% 90%